C4 Therapeutics Files 8-K: Other Events Reported

Ticker: CCCC · Form: 8-K · Filed: Oct 16, 2025 · CIK: 1662579

C4 Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyC4 Therapeutics, Inc. (CCCC)
Form Type8-K
Filed DateOct 16, 2025
Risk Levelmedium
Pages2
Reading Time3 min
Key Dollar Amounts$0.0001, $0.001, $9.6 m
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing

TL;DR

C4 Therapeutics filed an 8-K for 'Other Events' on Oct 16, 2025. Details TBD.

AI Summary

C4 Therapeutics, Inc. filed an 8-K on October 16, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, dollar amounts, or definitive dates beyond the filing date itself.

Why It Matters

This filing indicates that C4 Therapeutics has reported significant events to the SEC, but the lack of detail requires further investigation to understand the implications for the company.

Risk Assessment

Risk Level: medium — The filing is an 8-K for 'Other Events' without specific details, which can indicate significant but undisclosed developments.

Key Players & Entities

  • C4 Therapeutics, Inc. (company) — Registrant
  • October 16, 2025 (date) — Date of Report

FAQ

What specific 'Other Events' are being reported by C4 Therapeutics, Inc. in this 8-K filing?

The provided text of the 8-K filing does not specify the nature of the 'Other Events' beyond the general categorization.

What is the exact date of the earliest event reported in this 8-K?

The date of the earliest event reported is October 16, 2025.

What is the principal executive office address for C4 Therapeutics, Inc.?

The address of the Principal Executive Offices is 490 Arsenal Way, Suite 120, Watertown, MA 02472.

What is the Commission File Number for C4 Therapeutics, Inc.?

The Commission File Number for C4 Therapeutics, Inc. is 001-39567.

What is the IRS Employer Identification Number (EIN) for C4 Therapeutics, Inc.?

The IRS Employer Identification Number (EIN) for C4 Therapeutics, Inc. is 47-5617627.

Filing Stats: 722 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2025-10-16 06:30:13

Key Financial Figures

  • $0.0001 — ange on which registered Common Stock, $0.0001 par value per share CCCC The Nasdaq Glo
  • $0.001 — f the Company's common stock, par value $0.001 per share (" Common Stock "), from time
  • $9.6 m — wen for gross proceeds of approximately $9.6 million, before deducting commissions to

Filing Documents

01 Other Events

Item 8.01 Other Events. On October 16, 2025, C4 Therapeutics, Inc. (the " Company ") posted a presentation with data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone for the treatment of relapsed/refractory multiple myeloma. The presentation has been published to the "Events & Presentations" page of the investor relations section of the Company's website and is for use in meetings with investors, analysts and others. The presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Sales Agreement with TD Securities (USA) LLC Effective October 16, 2025, the Company terminated the sales agreement prospectus, dated November 13, 2024, related to the sale of shares of the Company's common stock, par value $0.001 per share (" Common Stock "), from time to time pursuant to the Sales Agreement, dated October 31, 2024, by and between TD Securities (USA) LLC (" TD Cowen ") and the Company (the " Sales Agreement "). As a result, the Company will not make any sales of Common Stock pursuant to the Sales Agreement, unless and until a new sales agreement prospectus supplement or a new registration statement with sales agreement prospectus is filed. The Sales Agreement remains in full force and effect. As of June 30, 2025, the Company had issued and sold 3,769,483 shares of its Common Stock under the Sales Agreement with TD Cowen for gross proceeds of approximately $9.6 million, before deducting commissions to TD Cowen. A copy of the Sales Agreement was filed as Exhibit 1.2 to the Company's Registration Statement on Form S-3 (File No. 333-282933), which was originally filed with the SEC on October 31, 2024, and declared effective on November 13, 2024.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . The exhibits shall be deemed to be filed or furnished, depending on the relevant item requiring such exhibit, in accordance with the provisions of Item 601 of Regulation S-K (17 CFR 229.601) and Instruction B.2 to this form. Exhibit Number Description 99.1 D a t a presentation dated October 16, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. C4 Therapeutics, Inc. Date: October 16, 2025 By: /s/ Jolie M. Siegel Jolie M. Siegel Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.